New Genetic Discovery Could Boost Cancer Immunotherapy

A recent genetic discovery has the potential to boost the effectiveness of cancer immunotherapy treatments. According to a study published in the journal Nature, the genetic discovery may improve cancer treatment outcomes in certain patients. Researchers stumbled upon the promising clue while they studied treatment outcomes in ovarian clear cell carcinoma (OCCC) patients post-immunotherapy.

The study was co-authored by Emily Hinchcliff, MD, an assistant professor of Obstetrics and Gynecology at Northwestern Medicine’s Division of Gynecologic Oncology. She notes that conventional cancer treatments such as radiation and chemotherapy are rarely effective against OCCC, an aggressive but rare form of ovarian cancer that is often unresponsive to conventional treatments. Immunotherapy also has a low success rate against OCCC and only works for a few patients, Hinchcliff says.

She says that even though immunotherapy changed how the medical industry approaches cancer treatment, the revolutionary approach has had little notable impact on ovarian cancer patients, especially those afflicted with ovarian clear cell carcinoma.

Hinchcliff and her colleagues conducted a study involving 34 patients who had been diagnosed with treatment-resistant OCCC and treated with immune checkpoint blockade, a type of immunotherapy that boosts the immune system’s ability to spot cancer cells and destroy them, to determine its treatment outcomes. Their findings revealed a median overall survival (OS) rate of 66.9 months, or over 5 years, in study participants with PPP2R1A-mutant OCCC. In comparison, patients who did not have the mutation had an overall survival rate of just 9.2 months after immunotherapy treatment.

The research team then studied two more patient cohorts that included a database containing more than 9,000 patients exposed to immunotherapy treatments. The scientists found that PPP2R1A mutations were associated with better treatment outcomes in several types of cancer. Even so, Hinchcliff cautioned against treating the mutation as an independent prognostic marker, stating that PPP2R1A seemed to induce a significant statistical improvement in overall survival rates in patients who had received checkpoint inhibitor treatments.

Using in vivo and in vitro models, the researchers determined that targeting the mutation caused an increase in immune cells called CD8+ T cells that can ‘remember’ and respond to threats quickly, leading to a stronger immune response post-treatment. These findings suggest that there may be a causal connection between PPP2R1A mutations and improved response in OCCC patients who received immunotherapy. The team is already building on its promising genetic discovery and has launched a clinical trial that will use immune checkpoint inhibitor treatments and target the mutation as well as associated molecular pathways to determine treatment outcomes for patients without the PPP2R1A mutations.

If successful, this research could pave the way for more personalized immunotherapy treatments and offer hope to patients with aggressive cancers that currently lack effective therapeutic options. By unlocking the potential of specific genetic mutations and their associated molecular pathways, scientists may accelerate the development of next-generation cancer therapies and improve survival outcomes worldwide.

With many teams, such as the one at Calidi Biotherapeutics Inc. (NYSE American: CLDI), working to bring immunotherapy to more cancer patients, the future of oncology looks brighter than it was decades ago.

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN